Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Response to Letter]

Fawzi Thomas,1,2 Onome T Abiri,2,3 Joyce M Kallon,4 Desmond Maada Kangbai,4 Thomas A Conteh,1,2 Sally-Mattu Conteh,4 Edna G Samuels,4 Olufunsho Awodele5 1Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone; 2Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone; 3Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone; 4Expanded Program on Immunization, Freetown, Sierra Leone; 5Department of Pharmacology, Therapeutics and Toxicology, College of Medicine, University of Lagos, Lagos, NigeriaCorrespondence: Fawzi Thomas, Department of Pharmaceutics, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone, Tel +23279460264, Email [email protected]